Mumbai: Sun Pharmaceutical Industries, India's largest drugmaker, on Friday reported a 36.2 per cent year-on-year decline in consolidated net profit to Rs 1,988.53 crore for the quarter ended September 2026 (Q2 FY27), hit by a one-time loss of Rs 1,269 crore, IANS reported, citing the company's stock exchange filing.
Source: IANS
The one-time charge was linked mainly to the proposed acquisition of Organon and litigation expenses in the US, The Hindu BusinessLine reported in its Q2 results coverage, adding that the company had posted a consolidated net profit of Rs 3,124.95 crore in the corresponding quarter last fiscal.
Source: The Hindu BusinessLine
Revenue from operations rose 11.9 per cent year on year to Rs 16,198.71 crore, compared with Rs 14,478.31 crore a year earlier. Excluding exceptional items, profit before tax stood at Rs 4,428.2 crore, up 6.3 per cent, while EBITDA rose 4.8 per cent to Rs 4,744 crore, though the EBITDA margin narrowed to 29.3 per cent from 31.3 per cent, IANS reported.
Source: IANS
Domestic formulation sales rose 17.3 per cent to Rs 5,552.3 crore and accounted for 34.5 per cent of consolidated sales, with the company's share of the Indian pharmaceutical market rising to 8.6 per cent from 8.3 per cent. Formulation sales in the United States fell 8.2 per cent to $455 million, while emerging-market formulation revenue rose 7.6 per cent to $350 million. Research and development spending was Rs 778.4 crore, or 4.8 per cent of sales, IANS reported.
Source: IANS
Sun Pharma is pursuing the proposed $11.75 billion acquisition of US-based Organon. Investors will watch the remaining approvals and closing timeline, and whether US sales recover, while the underlying business grew despite the one-time charge. Shares were trading 3.99 per cent higher at Rs 1,833.30 on the BSE during noon trade on Friday, IANS reported.